Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.90 | N/A | +12.29% |
management commentary, guidance changes, and full analysis available with Pro.
| +12.29% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings results, highlighting a commitment to innovation. They emphasized the importance of adapting to consumer demands.
We are pleased with our earnings performance this quarter.
Our focus remains on innovation and meeting consumer needs.
This earnings report indicates that Johnson & Johnson performed better than expected in terms of earnings per share. However, without revenue figures or stock reaction data, it's difficult to assess overall market sentiment. The lack of guidance may leave investors uncertain about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
YUM BRANDS INC
Jul 14, 2015